Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$21.66 -2.5%	$24.53	$21.48 ▼ $53.96	$1.02B	0.72	496,907 shs	449,057 shs
CYTK Cytokinetics	$37.01 +1.1%	$32.73	$29.31 ▼ $61.38	$4.42B	0.59	1.53 million shs	960,448 shs
RDUS Radius Recycling	$30.00	$29.59	$10.57 ▼ $30.04	$846.06M	1	469,507 shs	1.72 million shs
RYTM Rhythm Pharmaceuticals	$86.70 -2.6%	$64.34	$40.61 ▼ $94.80	$5.52B	2.26	588,517 shs	1.11 million shs
STOK Stoke Therapeutics	$11.86 -1.5%	$10.65	$5.35 ▼ $16.15	$647.52M	1.14	675,368 shs	545,119 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	-6.54%	-18.08%	-10.35%	-42.05%
CYTK Cytokinetics	0.00%	+9.17%	+11.48%	-4.24%	-32.62%
RDUS Radius Recycling	0.00%	+0.94%	+1.73%	+3.20%	+105.34%
RYTM Rhythm Pharmaceuticals	0.00%	+31.81%	+37.58%	+45.59%	+95.36%
STOK Stoke Therapeutics	0.00%	+3.27%	+0.34%	+68.95%	-10.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.3368 of 5 stars	3.1	2.0	0.0	3.7	2.0	4.2	1.3
CYTK Cytokinetics	4.0737 of 5 stars	4.5	1.0	0.0	4.6	2.2	0.8	0.0
RDUS Radius Recycling	1.8761 of 5 stars	1.0	2.0	0.8	2.6	2.6	1.7	0.0
RYTM Rhythm Pharmaceuticals	3.1905 of 5 stars	2.5	1.0	0.0	4.3	2.5	0.8	0.6
STOK Stoke Therapeutics	4.145 of 5 stars	3.7	1.0	0.0	4.8	2.2	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	49.28% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	91.63% Upside
RDUS Radius Recycling	2.00	Hold	$22.00	-26.67% Downside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.00	4.96% Upside
STOK Stoke Therapeutics	3.33	Buy	$24.75	108.68% Upside

Current Analyst Ratings Breakdown

Latest RYTM, STOK, RDUS, AMPH, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$88.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.39	$5.00 per share	4.33	$15.23 per share	1.42
CYTK Cytokinetics	$19.22M	229.99	N/A	N/A	($1.15) per share	-32.18
RDUS Radius Recycling	$2.74B	0.31	$0.73 per share	40.96	$18.73 per share	1.60
RYTM Rhythm Pharmaceuticals	$136.86M	40.30	N/A	N/A	$0.35 per share	247.71
STOK Stoke Therapeutics	$190.91M	3.39	N/A	N/A	$4.32 per share	2.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	7.85	6.58	5.64	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
RDUS Radius Recycling	-$266.41M	-$3.60	N/A	∞	N/A	-3.69%	-15.73%	-6.01%	N/A
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	15.01	N/A	N/A	26.33%	19.08%	15.72%	8/6/2025 (Estimated)

Latest RYTM, STOK, RDUS, AMPH, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	AMPH Amphastar Pharmaceuticals	$0.71	N/A	N/A	N/A	$173.42 million	N/A
8/6/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
7/1/2025	Q3 2025	RDUS Radius Recycling	-$0.87	-$0.39	+$0.48	-$0.59	$725.30 million	$726.99 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
RDUS Radius Recycling	$0.75	2.50%	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest RYTM, STOK, RDUS, AMPH, and CYTK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/26/2025	RDUS Radius Recycling	quarterly	$0.1875	2.53%	7/21/2025	7/21/2025	8/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
CYTK Cytokinetics	N/A	5.99	5.99
RDUS Radius Recycling	0.85	1.85	0.97
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
CYTK Cytokinetics	N/A
RDUS Radius Recycling	78.11%
RYTM Rhythm Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
CYTK Cytokinetics	2.70%
RDUS Radius Recycling	4.90%
RYTM Rhythm Pharmaceuticals	6.10%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
RDUS Radius Recycling	3,011	28.20 million	26.82 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

RYTM, STOK, RDUS, AMPH, and CYTK Headlines

Recent News About These Companies

Stoke City Boss Delighted To Finally Get Signing Over The Line

July 13 at 6:47 AM | therealefl.co.ukT

Grit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winter

July 13 at 6:47 AM | msn.com

Five of the best beer gardens around Stoke-on-Trent to enjoy in the sun

July 13 at 6:47 AM | msn.com

Man City prospect told to gain notoriety at Stoke City

July 13 at 6:47 AM | msn.com

Case builds for Biogen, Stoke's Dravet syndrome drug

July 11 at 4:18 PM | pharmaphorum.comP

Lille rival Aston Villa in race for Stoke’s Sol Sidibé

July 10 at 10:48 AM | sports.yahoo.com

Aston Villa want Stoke City midfielder Sol Sidibe

July 10 at 10:48 AM | sports.yahoo.com

Stoke City vs Shrewsbury LIVE Score Updates: Match Canceled

July 10 at 10:48 AM | vavel.comV

Council still against Stoke-on-Trent 'merger' as devolution decision gets nearer

July 10 at 10:48 AM | msn.com

Live updates after 'accident' on Stoke-on-Trent road

July 10 at 10:48 AM | stokesentinel.co.ukS

Stoke City close in on fourth summer signing

July 10 at 10:48 AM | msn.com

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10 at 7:00 AM | globenewswire.com

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10 at 7:00 AM | businesswire.com

Live updates as firefighters on scene of Stoke-on-Trent blaze

July 8, 2025 | stokesentinel.co.ukS

Police helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent park

July 8, 2025 | msn.com

Stoke-on-Trent firm collapses into administration

July 8, 2025 | msn.com

Driver dies in Royal Stoke after hitting tree

July 8, 2025 | msn.com

Stoke City move early for 'lethal' rising Manchester City star in second signing of the day

July 7, 2025 | msn.com

New Hanford waste incinerator could keep patients warm at Royal Stoke

July 7, 2025 | msn.com

Stoke sign Talovierov and Man City's Mubama

July 7, 2025 | msn.com

Stoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLC

July 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM, STOK, RDUS, AMPH, and CYTK Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$21.66 -0.55 (-2.48%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$22.12 +0.45 (+2.10%)

As of 07/11/2025 07:57 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Cytokinetics NASDAQ:CYTK

$37.01 +0.42 (+1.15%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$35.93 -1.08 (-2.92%)

As of 07/11/2025 07:45 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Radius Recycling NASDAQ:RDUS

$30.00 0.00 (0.00%)

Closing price 07/10/2025 06:09 PM Eastern

Extended Trading

$30.00 0.00 (0.00%)

As of 07/10/2025 06:09 PM Eastern

Radius Recycling, Inc. recycles ferrous and nonferrous metal, and manufactures finished steel products worldwide. The company acquires, processes, and recycles salvaged vehicles, rail cars, home appliances, industrial machinery, manufacturing scrap, and construction and demolition scrap. It offers recycled ferrous metal, a feedstock used in the production of finished steel products; and nonferrous products, including mixed metal joint products recovered from the shredding process, such as zorba, zurik, aluminum, copper, stainless steel, nickel, brass, titanium, lead, and high temperature alloys. The company also procures salvaged vehicles and sells serviceable used auto parts from these vehicles through its retail self-service auto parts stores. In addition, it produces various finished steel products using ferrous recycled metal and other raw materials, as well as semi-finished goods, which include billets; and finished goods consisting of rebar, coiled rebar, wire rods, merchant bars, and other specialty products. Further, the company sells catalytic converters to specialty processors that extract the nonferrous precious metals, including platinum, palladium, and rhodium; and ferrous and nonferrous recycled metal products to steel mills, foundries, refineries, smelters, wholesalers, and recycled metal processors, as well as finished steel customers, such as steel service centers, construction industry subcontractors, steel fabricators, wire drawers, and major farm and wood products suppliers. It also provides recycling and related services, including scrap brokerage, certified destruction, automotive parts recycling, railcar dismantling, and reverse logistics under 3PR brand name. Radius Recycling, Inc. was formerly known as Schnitzer Steel Industries, Inc. and changed its name to Radius Recycling, Inc. in January 2024. Radius Recycling, Inc. was founded in 1906 and is headquartered in Portland, Oregon.

Rhythm Pharmaceuticals NASDAQ:RYTM

$86.70 -2.34 (-2.63%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$88.35 +1.65 (+1.90%)

As of 07/11/2025 07:32 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$11.86 -0.18 (-1.50%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.86 0.00 (0.00%)

As of 07/11/2025 04:04 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time